OFF-TARGET RESOURCE CORE
- Institution
- CHILDREN'S HOSP OF PHILADELPHIA, PA
- Principal investigator
- Xiao Wang
- Funding
- $712K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Off-target editing analyses will be so fundamental to the development of our therapeutic leads, regardless of the disease treated—whether phenylketonuria (Lead Project 1), hereditary tyrosinemia type 1 (Project 2), or mucopolysaccharidosis type I (Project 3)—and so integral to any IND applications that ultimately emerge from the Projects, that we are proposing an Off-Target Resource Core that will serve all three Research Projects. This Resource Core will provide services that are directly aligned with the preclinical studies that are recommended by the U.S. Food and Drug Administration (FDA) Draft Guidance for Industry on Human Gene Therapy Products Incorporating Human Genome Editing, namely: (1) identification of on-target and off-target editing activity, including the type, frequency, and location of all off-target editing events, taking into account human genetic variation; (2) assessment of genomic integrity, including chromosomal rearrangements, large insertions, or large deletions; and (3) evaluation of the biological consequences associated with off-target editing.
LOADING MOONBASE SCORE
Questions for CHILDREN'S HOSP OF PHILADELPHIA
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of PennsylvaniaNot yet scored
Corrective editing to treat phenylketonuria
Xiao Wang · $675K · 2024–2029
- NIH · Children'S Hosp of PhiladelphiaReviewed
Effects of Sleep on Bone Density and Strength in Adolescence: A Prospective Longitudinal Study
Jonathan Andrew Mitchell · $652K · 2020–2026
- NIH · Children'S Hosp of PhiladelphiaNot yet scored
Reducing Disparities in Access to High-level Neonatal Intensive Care and Neonatal Outcomes
Erika M. Edwards · $736K · 2025–2030